Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a report published on Tuesday. The brokerage issued a sell rating on the stock.

Senseonics Price Performance

SENS opened at $0.41 on Tuesday. The stock’s 50 day moving average price is $0.44 and its 200-day moving average price is $0.53. Senseonics has a 52-week low of $0.37 and a 52-week high of $1.05. The stock has a market capitalization of $216.81 million, a PE ratio of -2.92 and a beta of 0.82. The company has a debt-to-equity ratio of 1.79, a quick ratio of 3.70 and a current ratio of 3.96.

Senseonics (NYSE:SENS) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). Senseonics had a negative net margin of 346.38% and a negative return on equity of 202.32%. The business had revenue of $5.05 million for the quarter, compared to the consensus estimate of $4.76 million. On average, equities research analysts predict that Senseonics will post -0.13 EPS for the current year.

Institutional Trading of Senseonics

Large investors have recently bought and sold shares of the company. RPO LLC purchased a new position in shares of Senseonics in the 4th quarter valued at approximately $37,000. State Board of Administration of Florida Retirement System purchased a new position in Senseonics during the first quarter valued at $91,000. Virtu Financial LLC bought a new stake in shares of Senseonics during the 1st quarter valued at $162,000. Price T Rowe Associates Inc. MD grew its position in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after buying an additional 51,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after acquiring an additional 211,128 shares in the last quarter. 12.36% of the stock is owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.